A SEM of a nanopatch
A SEM of a nanopatch

Needle-free vaccination research conducted at the AIBN has received further funding from the Queensland State Government.

Announced at the recent Bio Industry Organisation meeting iheld n Boston, Professor Mark Kendall will receive a $1.24 million Innovation Projects Fund grant to develop his nanopatch technology.

The project also received funding from the Seattle Biomedical Research Insitute, the Program for Appropriate Technology in Health (PATH) and the World Health Organisation, bringing the total investment to $3.5 million.

According to Professor Kendall the nanopatch will deliver its payload of vaccine to specific cells just below the sruface of the skin using tiny projections manufactured on the micro- and nanometre scale.

"This method of vaccine delivery does not rely on needles, is painless and also offers significant practical advantages in the developing world because the vaccine will not require refrigeration," he said.

"Needles are very effective in delivering vaccines to trigger an antibody response for diseases such as measles, however malaria, tuberculosis and HIV require a strong killer T-cell response which is not stimulated by current vaccinations.

"By targeting the immunological cells found less than a hair's breadth under the surface of the skin we hope to stimulate the appropriate response to combat these diseases."

Professor Kendall added that because nerve cells were found well below the level to which the nano-projections penetrate, appling a patch was painless and unlikely to cause any irritation.

This multi disciplinary research spans biomedical enfineering, diagnostics, dermatology and vacciniology and involves collaborations with 2006 Australian of the Professor Ian Frazer and the Diamantina Institute for Cancer Immunology and Metabolic Medicine, as well as substantial links with UQ's Faculty of Health Sciences.

On this site